Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

NCT07680790 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

850

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Iza-bren
DRUG: Osimertinib
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Cisplatin

Sponsor

Bristol-Myers Squibb